Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily…
Articles by Forest Ray PhD
The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide)…
The Multiple Myeloma Research Foundation (MMRF) is partnering with Indapta Therapeutics to advance the biotechnology company’s investigational G-NK…
The Dana-Farber Cancer Institute and Quest Diagnostics, the laboratory testing company, are conducting a study to measure the…
An independent data monitoring committee has recommended that the GENESIS Phase 3 trial evaluating motixafortide (formerly BL-8040), as a…
After first rejecting a Sarclisa (isatuximab) triple combination therapy due to cost-effectiveness concerns, the U.K.’s National…
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to oNKord, Glycostem…
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a…